Pulmonary infectious complications of tumor necrosis factor blockadeRobert S Wallis
Pfizer, New London, CT 06320, USA
Infect Dis Clin North Am 24:681-92. 2010
..Further research is needed to determine how best to prevent and manage their infectious complications and to determine their potential adjunctive therapeutic role in chronic infectious diseases...
Infectious complications of tumor necrosis factor blockadeRobert S Wallis
Pfizer, New London, Connecticut 06320, USA
Curr Opin Infect Dis 22:403-9. 2009
....
Adalimumab treatment of life-threatening tuberculosisRobert S Wallis
Pfizer, New London, Connecticut 06320, USA
Clin Infect Dis 48:1429-32. 2009
..Clinical improvement occurred only after resumption of adalimumab treatment...
Strain specificity of antimycobacterial immunity in whole blood culture after cure of tuberculosisRobert S Wallis
Pfizer Specialty Care, New London, CT 06320, USA
Tuberculosis (Edinb) 89:221-4. 2009
..However, additional studies will be required to confirm these observations in additional patient and microbial populations that are distinct according to geography and microbial and host genetics...
Tumour necrosis factor antagonists: structure, function, and tuberculosis risksRobert S Wallis
PPD Inc, Washington, DC, USA
Lancet Infect Dis 8:601-11. 2008
..Clinical strategies for prevention and management of tuberculosis in patients treated with TNF blockers may be improved based on our evolving understanding of these differences...
Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosisRobert S Wallis
Pfizer, Groton New London, CT 06320, USA
Antimicrob Agents Chemother 55:567-74. 2011
..06 log) (P = 0.002). In conclusion, PNU-100480 was safe and well tolerated at all tested doses. Further studies in patients with tuberculosis are warranted. Biomarkers can accelerate early development of new tuberculosis treatments...
Tuberculosis biomarkers discovery: developments, needs, and challengesRobert S Wallis
Specialty Care, Pfizer, Groton, CT, USA
Lancet Infect Dis 13:362-72. 2013
..We review progress in tuberculosis biomarker development and efforts being made to harness resources to meet future challenges...
Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practiceRobert S Wallis
Pfizer, New London, CT, USA
Lancet 375:1920-37. 2010
..Translation of scientific progress in biomarkers and diagnostics into clinical and public health programmes is possible-with political commitment, increased funding, and engagement of all stakeholders...
Mathematical modeling of the cause of tuberculosis during tumor necrosis factor blockadeRobert S Wallis
PPD Inc, Washington, DC 20005, USA
Arthritis Rheum 58:947-52. 2008
..These 2 pathogenic mechanisms cannot otherwise be readily distinguished...
Reactivation of latent tuberculosis by TNF blockade: the role of interferon gammaRobert S Wallis
PPD, Washington, DC, USA
J Investig Dermatol Symp Proc 12:16-21. 2007
..IL-10 production was equally suppressed by all three drugs, excluding excess IL-10 as a regulatory mechanism. The tuberculosis risk posed by infliximab may reflect its combined effects on TNF and IFNgamma...
Pharmacokinetics and whole-blood bactericidal activity against Mycobacterium tuberculosis of single doses of PNU-100480 in healthy volunteersRobert S Wallis
Pfizer, 50 Pequot Avenue, New London, CT 06320, USA
J Infect Dis 202:745-51. 2010
..Two metabolites contribute to but do not fully account for its superiority. This study examined the safety, tolerability, pharmacokinetics, and mycobactericidal activity of single ascending doses of PNU-100480...
Biomarkers for tuberculosis disease activity, cure, and relapseRobert S Wallis
Pfizer, New London, USA
Lancet Infect Dis 9:162-72. 2009
..These studies will benefit from multidisciplinary collaborations including microbiologists, immunologists, clinicians, tuberculosis control personnel, and the pharmaceutical and biotechnology industry...
Biologics and infections: lessons from tumor necrosis factor blocking agentsRobert S Wallis
Department of Specialty Care, Pfizer, Groton, CT 06340, USA
Infect Dis Clin North Am 25:895-910. 2011
..This article focuses on recent studies that inform prevention and management of infections in this susceptible patient population...
Reconsidering adjuvant immunotherapy for tuberculosisRobert S Wallis
PPD, Washington, DC, USA
Clin Infect Dis 41:201-8. 2005
..Prolonged treatment is presently required to prevent relapse, which is thought to arise from persisting foci of semidormant infection contained within granulomas...
Anti-tuberculosis treatment and infliximabRobert S Wallis
Respir Med 99:1620-2. 2005
Structural-functional relationships of TNF-alpha antagonists: next stepsFrank J Dann
Amgen Inc, Thousand Oaks, California 91320 1799, USA
J Investig Dermatol Symp Proc 12:46-7. 2007
..The data presented in this supplement highlight the need for further research into these key areas, and illustrate our current understanding of the mode of action of TNF blockers as only the tip of the iceberg...
A study of the immunology, virology, and safety of prednisone in HIV-1-infected subjects with CD4 cell counts of 200 to 700 mm(-3)Robert S Wallis
The University Medicine and Dentistry of New Jersey New Jersey Medical School, Newark, USA
J Acquir Immune Defic Syndr 32:281-6. 2003
..The potential role of corticosteroids as tools to examine this question will be limited by concerns regarding their toxicity; however, further studies of other agents to limit cellular activation in AIDS are warranted...
A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosisRobert S Wallis
Department of Medicine, Case Western Reserve University, Cleveland, OH, USA
AIDS 18:257-64. 2004
..This phase 1 study examined the safety, microbiology, immunology, and virology of TNF blockade using etanercept (soluble TNF receptor, Enbrel) during the initial treatment of HIV-associated tuberculosis...
Persistence, not resistance, is the cause of loss of isoniazid effectRobert S Wallis
J Infect Dis 195:1870-1; author reply 1872-3. 2007
Granulomatous infections due to tumor necrosis factor blockade: correctionRobert S Wallis
Clin Infect Dis 39:1254-5. 2004
Tumor necrosis factor and granuloma biology: explaining the differential infection risk of etanercept and infliximabRobert S Wallis
UMDNJ New Jersey Medical School, Newark, NJ, USA
Semin Arthritis Rheum 34:34-8. 2005
..TNF is known to participate in the induction and maintenance of protective granulomas at multiple steps, and evidence supporting a differential inhibition of TNF bioactivity and signaling by the 2 drugs is discussed...
Reactivation of latent granulomatous infections by infliximabRobert S Wallis
University of Medicine and Dentistry New Jersey, New Jersey Medical School, Newark, New Jersey, USA
Clin Infect Dis 41:S194-8. 2005
..The ability of infliximab to disrupt established granulomas may be distinct from its ability to neutralize soluble TNF. Further research to elucidate the mechanism of the antigranuloma activity of infliximab is warranted...
Tumor-necrosis-factor blockers: differential effects on mycobacterial immunityOluwabunmi Y Saliu
Department of Medicine, University of Medicine and Dentistry, New Jersey Medical School, Newark, USA
J Infect Dis 194:486-92. 2006
..tuberculosis. None of the drugs induced significant levels of apoptosis or necrosis, in either monocytes or T cells. CONCLUSIONS: The tuberculosis risk posed by infliximab may reflect its combined effects on TNF and IFN- gamma ...
Bactericidal activity in whole blood as a potential surrogate marker of immunity after vaccination against tuberculosisSeon-Hee Cheon
Case Western Reserve University, Cleveland, Ohio, USA
Clin Diagn Lab Immunol 9:901-7. 2002
..These experiments indicate that whole blood culture may be used to measure immunity to M. tuberculosis and that further studies of repeated BCG vaccination are warranted...